Table 1 Patient demographics in the overall population, 332 advanced or recurrent NSCLC who received 1st or 2nd generation EGFR TKI.

From: Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer

Characteristics

All (N = 332)

De novo resistance (N = 28)

Intermediate responders (N = 240)

Long-term responders (N = 64)

P values

Age at diagnosis, n (%)

    

0.44

Median (IQR)

64 (54.3–72)

60.5 (50–68)

64 (55–72)

63 (55–72)

 

 < 60 years

136 (41%)

14 (50%)

99 (41.3%)

23 (35.9%)

 

 ≥ 60 years

196 (59%)

14 (50%)

141 (58.7%)

41 (64.1%)

 

Gender, n (%)

    

0.56

Male

118 (35.5%)

12 (42.9%)

86 (35.8%)

20 (31.3%)

 

Female

214 (64.5%)

16 (57.1%)

154 (64.2%)

44 (68.8%)

 

ECOG PS, n (%)

    

0.07

0–1

272 (86.6%)

21 (75%)

197 (86.4%)

54 (93.1%)

 

 ≥ 2

42 (13.4%)

7 (25%)

31 (13.6%)

4 (6.9%)

 

Missing

18

 

12

6

 

Smoking status, n (%)

    

0.10

Never

229 (80.4%)

16 (64%)

168 (82%)

45 (81.8%)

 

Current/former

56 (19.6%)

9 (36%)

37 (18%)

10 (18.2%)

 

Missing

47

3

35

9

 

Histology, n (%)

    

0.48

Adenocarcinoma

310 (95.4%)

28 (100%)

225 (95%)

57 (95%)

 

Non adenocarcinoma

15 (4.6%)

0

12 (5%)

3 (5%)

 

Missing

7

 

3

4

 

Stage at diagnosis, n (%)

    

0.003*

Recurrent

79 (23.8%)

1 (3.6%)

55 (22.9%)

23 (35.9%)

 

Metastatic

253 (76.2%)

27 (96.4%)

185 (77.1%)

41 (64.1%)

 

Curative surgery, n (%)

70 (21.1%)

1 (3.6%)

48 (20%)

21 (32.8%)

0.01*

Number of metastatic sites, n (%)

    

0.002*

1–2 sites

248 (74.7%)

20 (71.4%)

169 (70.4%)

59 (92.2%)

 

 ≥ 3 sites

84 (25.3%)

8 (28.6%)

71 (29.6%)

5 (7.8%)

 

Brain metastasis, n (%)

73 (22%)

9 (32.1%)

54 (22.5%)

10 (15.6%)

0.20

Liver metastasis, n (%)

37 (11.1%)

2 (7.1%)

29 (12.1%)

6 (9.4%)

0.65

EGFR mutation subtypes, n (%)

    

 < 0.001*

Del19

169 (50.9%)

10 (35.7%)

126 (52.5%)

33 (51.6%)

 

L858R

136 (41%)

10 (35.7%)

98 (40.8%)

28 (43.8%)

 

G719X

6 (1.8%)

3 (10.7%)

3 (1.3%)

0

 

L861G or Q

6 (1.8%)

3 (10.7%)

3 (1.3%)

0

 

S768I

1 (0.3%)

0

1 (0.4%)

0

 

Exon 20 insertion

2 (0.6%)

1 (3.6%)

1 (0.4%)

0

 

Any or combined mutations

12 (3.6%)

1 (3.6%)

8 (3.3%)

3 (4.7%)

 

EGFR mutation subtypes, n (%)

    

 < 0.001*

Del19

169 (50.9%)

10 (35.7%)

126 (52.5%)

33 (51.6%)

 

L858R

136 (41%)

10 (35.7%)

98 (40.8%)

28 (43.8%)

 

Uncommona

15 (4.5%)

7 (25%)

8 (3.3%)

0

 

Any or combined mutations

12 (3.6%)

1 (3.6%)

8 (3.3%)

3 (4.7%)

 

Line of EGFR TKIs, n (%)

    

0.21

First line

218 (65.7%)

17 (60.7%)

153 (63.8%)

48 (75%)

 

Later line

114 (34.3%)

11 (39.3%)

87 (36.3%)

16 (25%)

 

Type of EGFR TKIs, n (%)

    

0.01*

Gefitinib

197 (59.3%)

17 (60.7%)

145 (60.4%)

35 (54.7%)

 

Erlotinib

121 (36.4%)

8 (28.6%)

84 (35%)

29 (45.3%)

 

2nd generationb

14 (4.3%)

3 (10.7%)

11 (4.6%)

0

 

Duration of TKI treatment, median (IQR, months)

12.4 (7.1–20.5)

2.3 (1.6–3)

11.9 (7.6–15.9)

32.4 (27.8–37.3)

 < 0.001*

ORR, n (%)

201 (60.5%)

1 (3.6%)

159 (66.2%)

41 (64.1%)

 < 0.001*

  1. aUncommon EGFR mutations, including G719X in exon 18 (n = 6), exon 20 insertion (n = 2), S768I in exon 20 (n = 1) and L861G or Q in exon 21 (n = 6). bAfatinib and dacomitinib were used in 13 and 1 patients, respectively.
  2. Del19 exon 19 deletion, ECOG PS Eastern Cooperative Oncology Group performance status, EGFR epidermal growth factor receptor, IQR interquartile range, ORR overall response rate.
Back to article page